Suppr超能文献

心脏和肾脏同时移植后的肾脏结局。

Renal outcome after simultaneous heart and kidney transplantation.

机构信息

Department of Urology and Transplant Surgery, Hôpital Européen Georges-Pompidou, AP-HP, Université de Paris, Paris, France.

Department of Urology and Transplant Surgery, Hôpital Edouard-Herriot, Hospices Civils de Lyon, Lyon, France.

出版信息

Clin Transplant. 2019 Jul;33(7):e13615. doi: 10.1111/ctr.13615. Epub 2019 Jun 19.

Abstract

Simultaneous heart-kidney transplant (HKTx) is a valid treatment for patients with coexisting heart and renal failure. The aim of this study was to assess renal outcome in HKTx and to identify predictive factors for renal loss. A retrospective study was conducted among 73 HKTx recipients: Donors' and recipients' records were reviewed to evaluate patients' and renal transplants' survival and their prognostic factors. The mean follow-up was 5.36 years. Renal primary non-function occurred in 2.7%, and complications Clavien IIIb or higher were observed in 67.1% including 16 (22%) postoperative deaths. Five-year overall survival and renal survival were 74.5% and 69.4%. Among survivors, seven returned to dialysis during follow-up. The postoperative use of ECMO (HR = 6.04, P = 0.006), dialysis (HR = 1.04/day, P = 0.022), and occurrence of complications (HR = 31.79, P = 0.022) were independent predictors of postoperative mortality but not the history of previous HTx or KTx nor renal function prior to transplantation. History of KTx (HR = 2.52, P = 0.026) and increased delay between the two transplantations (HR = 1.25/hour, P = 0.018) were associated with renal transplant failure. HKTx provides good renal transplant survival and function, among survivors. Early mortality rate of 22% underlines the need to identify perioperative risk factors that would lead to more judicious and responsible allocation of a scarce resource.

摘要

心脏-肾脏联合移植(HKTx)是治疗并存心力衰竭和肾衰竭患者的有效方法。本研究旨在评估 HKTx 的肾脏预后,并确定肾脏丧失的预测因素。对 73 例 HKTx 受者进行了回顾性研究:回顾了供者和受者的记录,以评估患者和肾移植的存活率及其预后因素。平均随访时间为 5.36 年。肾原发性无功能发生率为 2.7%,并发症为 Clavien IIIb 或更高,包括 16 例(22%)术后死亡。5 年总生存率和肾存活率分别为 74.5%和 69.4%。在幸存者中,有 7 人在随访期间重新开始透析。术后使用 ECMO(HR=6.04,P=0.006)、透析(HR=1.04/天,P=0.022)和并发症的发生(HR=31.79,P=0.022)是术后死亡的独立预测因素,但与既往 HTx 或 KTx 史或移植前肾功能无关。KTx 史(HR=2.52,P=0.026)和两次移植之间的时间延迟增加(HR=1.25/小时,P=0.018)与肾移植失败相关。在幸存者中,HKTx 提供了良好的肾移植存活率和功能。22%的早期死亡率强调需要确定围手术期风险因素,以便更明智和负责任地分配稀缺资源。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验